The University of Southampton
University of Southampton Institutional Repository

Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry

Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry
Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry
Objectives: idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) and the most common idiopathic interstitial pneumonia. The UK IPF Registry was established in 2013 to collect data pertaining to clinical features, therapeutic approaches and outcomes. From February 2023, the Registry expanded to include any ILD with evidence of fibrosis.

Design: the UK IPF Registry is a national, multicentre observational registry, including both prospective and retrospective data of patients with IPF in secondary or tertiary care. Cases eligible for inclusion were those with a diagnosis of IPF, presenting at participating centres from January 2013.

Results: between January 2013 and February 2023, 5052 IPF cases were registered from 64 participating centres. There was a male preponderance (77.8%) with mean±SD age of 74±8.1 years, 66% were ex-smokers and 76% had at least one comorbidity. Over a third (36.7%) experienced symptoms for more than 24 months prior to their first clinic visit. The majority of cases were discussed at a multidisciplinary team (MDT) meeting and the most common radiological patterns at presentation were probable (54.6%) and definite (42.7%) usual interstitial pneumonia. There was a reduction in surgical lung biopsies from 14% in 2013 to 5.5% in 2022. Antifibrotic therapy prescription rose from 36.0% in 2013 to 55.9% in 2023. The use of nintedanib (approved by National Institute of Clinical Excellence in January 2016) rose from 6.7% in 2013 to 31.5% in 2022 and pirfenidone (approved in April 2013) was initially used in around a third of cases before dropping to between 16.8% and 24.9% after nintedanib was approved.

Conclusion: these data reflect clinical practice across the UK and it is intended the data will have a role in informing the future of IPF care and providing a model for benchmarking, ultimately increasing knowledge and improving clinical care for this devastating disease.
2052-4439
Fahim, Ahmed
21deac54-d439-41ef-8b7f-11b4c4f3bf3d
Loughenbury, Maria
d8e4f35c-9e42-42f5-b79c-26f8dbdf2373
Stewart, Iain
e2ffcbf9-b394-4101-a0dd-8bc026e60fcb
Agnew, Sarah
3b2e34da-51df-4727-8c0b-f317742f2985
Almond, Howard
3b688cca-54a1-4ee9-9ed3-5514c63614b4
Casimo, Leo
c288e0a4-f51f-4277-a7d0-6ca7f820d69e
Chaudhuri, Nazia
24ec6e3a-3bcc-4cbd-bd8b-2b47633b3d28
Fletcher, Sophie V.
71599088-9df7-4d4a-8570-aef773ead0fe
Haney, Sarah
f91bc1c0-9440-4262-95e5-f5c29ea39e0b
Ho, Ling-Pei
4b3b02d9-5533-4d96-98af-f226087d0d00
Hodkinson, Clare
3b1bd9e1-ca68-470a-b9e5-0f73722f646d
Minnis, Paul
1cb517ac-3162-42b9-89f7-767e51c13757
Palmer, Evelyn
9e1c9828-7ae8-4f1e-bd17-5b05f8a7ae25
Wilson, Andrew M.
536dc43f-17cb-4501-8d07-ec938676a0f6
Fahim, Ahmed
21deac54-d439-41ef-8b7f-11b4c4f3bf3d
Loughenbury, Maria
d8e4f35c-9e42-42f5-b79c-26f8dbdf2373
Stewart, Iain
e2ffcbf9-b394-4101-a0dd-8bc026e60fcb
Agnew, Sarah
3b2e34da-51df-4727-8c0b-f317742f2985
Almond, Howard
3b688cca-54a1-4ee9-9ed3-5514c63614b4
Casimo, Leo
c288e0a4-f51f-4277-a7d0-6ca7f820d69e
Chaudhuri, Nazia
24ec6e3a-3bcc-4cbd-bd8b-2b47633b3d28
Fletcher, Sophie V.
71599088-9df7-4d4a-8570-aef773ead0fe
Haney, Sarah
f91bc1c0-9440-4262-95e5-f5c29ea39e0b
Ho, Ling-Pei
4b3b02d9-5533-4d96-98af-f226087d0d00
Hodkinson, Clare
3b1bd9e1-ca68-470a-b9e5-0f73722f646d
Minnis, Paul
1cb517ac-3162-42b9-89f7-767e51c13757
Palmer, Evelyn
9e1c9828-7ae8-4f1e-bd17-5b05f8a7ae25
Wilson, Andrew M.
536dc43f-17cb-4501-8d07-ec938676a0f6

Fahim, Ahmed, Loughenbury, Maria, Stewart, Iain, Agnew, Sarah, Almond, Howard, Casimo, Leo, Chaudhuri, Nazia, Fletcher, Sophie V., Haney, Sarah, Ho, Ling-Pei, Hodkinson, Clare, Minnis, Paul, Palmer, Evelyn and Wilson, Andrew M. (2025) Idiopathic pulmonary fibrosis in the UK: findings from the British Thoracic Society UK Idiopathic Pulmonary Fibrosis Registry. BMJ Open Respiratory Research, 12, [e002773]. (doi:10.1136/ bmjresp-2024-002773).

Record type: Article

Abstract

Objectives: idiopathic pulmonary fibrosis (IPF) is a progressive interstitial lung disease (ILD) and the most common idiopathic interstitial pneumonia. The UK IPF Registry was established in 2013 to collect data pertaining to clinical features, therapeutic approaches and outcomes. From February 2023, the Registry expanded to include any ILD with evidence of fibrosis.

Design: the UK IPF Registry is a national, multicentre observational registry, including both prospective and retrospective data of patients with IPF in secondary or tertiary care. Cases eligible for inclusion were those with a diagnosis of IPF, presenting at participating centres from January 2013.

Results: between January 2013 and February 2023, 5052 IPF cases were registered from 64 participating centres. There was a male preponderance (77.8%) with mean±SD age of 74±8.1 years, 66% were ex-smokers and 76% had at least one comorbidity. Over a third (36.7%) experienced symptoms for more than 24 months prior to their first clinic visit. The majority of cases were discussed at a multidisciplinary team (MDT) meeting and the most common radiological patterns at presentation were probable (54.6%) and definite (42.7%) usual interstitial pneumonia. There was a reduction in surgical lung biopsies from 14% in 2013 to 5.5% in 2022. Antifibrotic therapy prescription rose from 36.0% in 2013 to 55.9% in 2023. The use of nintedanib (approved by National Institute of Clinical Excellence in January 2016) rose from 6.7% in 2013 to 31.5% in 2022 and pirfenidone (approved in April 2013) was initially used in around a third of cases before dropping to between 16.8% and 24.9% after nintedanib was approved.

Conclusion: these data reflect clinical practice across the UK and it is intended the data will have a role in informing the future of IPF care and providing a model for benchmarking, ultimately increasing knowledge and improving clinical care for this devastating disease.

Text
e002773.full - Version of Record
Download (1MB)

More information

Accepted/In Press date: 7 January 2025
Published date: 19 February 2025

Identifiers

Local EPrints ID: 500932
URI: http://eprints.soton.ac.uk/id/eprint/500932
ISSN: 2052-4439
PURE UUID: dd367c75-6863-4a02-b136-bc7f0b9c8d02
ORCID for Sophie V. Fletcher: ORCID iD orcid.org/0000-0002-5633-905X

Catalogue record

Date deposited: 19 May 2025 16:41
Last modified: 22 Aug 2025 02:45

Export record

Altmetrics

Contributors

Author: Ahmed Fahim
Author: Maria Loughenbury
Author: Iain Stewart
Author: Sarah Agnew
Author: Howard Almond
Author: Leo Casimo
Author: Nazia Chaudhuri
Author: Sophie V. Fletcher ORCID iD
Author: Sarah Haney
Author: Ling-Pei Ho
Author: Clare Hodkinson
Author: Paul Minnis
Author: Evelyn Palmer
Author: Andrew M. Wilson

Download statistics

Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.

View more statistics

Atom RSS 1.0 RSS 2.0

Contact ePrints Soton: eprints@soton.ac.uk

ePrints Soton supports OAI 2.0 with a base URL of http://eprints.soton.ac.uk/cgi/oai2

This repository has been built using EPrints software, developed at the University of Southampton, but available to everyone to use.

We use cookies to ensure that we give you the best experience on our website. If you continue without changing your settings, we will assume that you are happy to receive cookies on the University of Southampton website.

×